Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
German Center for Lung Research (DZL), partner site Munich, Munich, Germany.
Radiat Oncol. 2020 Sep 10;15(1):214. doi: 10.1186/s13014-020-01654-9.
Lung, breast, and esophageal cancer represent three common malignancies with high incidence and mortality worldwide. The management of these tumors critically relies on radiotherapy as a major part of multi-modality care, and treatment-related toxicities, such as radiation-induced pneumonitis and/or lung fibrosis, are important dose limiting factors with direct impact on patient outcomes and quality of life. In this review, we summarize the current understanding of radiation-induced pneumonitis and pulmonary fibrosis, present predictive factors as well as recent diagnostic and therapeutic advances. Novel candidates for molecularly targeted approaches to prevent and/or treat radiation-induced pneumonitis and pulmonary fibrosis are discussed.
肺癌、乳腺癌和食管癌是三种常见的恶性肿瘤,全球发病率和死亡率都很高。这些肿瘤的治疗主要依赖于放射治疗,作为多模式治疗的重要组成部分,治疗相关的毒性,如放射性肺炎和/或肺纤维化,是重要的剂量限制因素,直接影响患者的结局和生活质量。在这篇综述中,我们总结了目前对放射性肺炎和肺纤维化的认识,介绍了预测因素以及最近的诊断和治疗进展。讨论了用于预防和/或治疗放射性肺炎和肺纤维化的分子靶向治疗的新候选药物。